Skip to main content

Cencora, Inc. stock price and financials

  • COR · NYSE
  • Distribution
  • Health Care Distributors
  • S&P 500
$359.03+2.76%Close 13 Nov 2026
Market value
$68.14B
P/E
25.96
EV / EBITDA
19.02
Dividend yield
0.7%
Beta · 1 year
0.05
Return · 1 year
−1.2%
52-week range$244.82 — $377.54

Share price close 16 Nov 2026

+4.6%1 monthHigh $359.03Low $324.35
$320$330$340$350$36023 Oct29 Oct4 Nov10 Nov16 Nov
+38.5%6 monthsHigh $359.03Low $261.87
$250$275$300$325$350$375Q3 FY2026 report filed 5 Aug 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+5.7%year to dateHigh $372.65Low $252.74
$250$300$350$400Q1 FY2026 report filed 4 Feb 2026Q2 FY2026 report filed 6 May 2026Q3 FY2026 report filed 5 Aug 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
−1.4%1 yearHigh $374.75Low $252.74
$250$300$350$400Q4 FY2025 report filed 25 Nov 2025Q1 FY2026 report filed 4 Feb 2026Q2 FY2026 report filed 6 May 2026Q3 FY2026 report filed 5 Aug 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+84.8%3 yearsHigh $374.75Low $195.00
$150$200$250$300$350$400Q4 FY2023 report filed 21 Nov 2023Q1 FY2024 report filed 31 Jan 2024Q2 FY2024 report filed 1 May 2024Q3 FY2024 report filed 31 Jul 2024Q4 FY2024 report filed 26 Nov 2024Q1 FY2025 report filed 5 Feb 2025Q2 FY2025 report filed 7 May 2025Q3 FY2025 report filed 6 Aug 2025Q4 FY2025 report filed 25 Nov 2025Q1 FY2026 report filed 4 Feb 2026Q2 FY2026 report filed 6 May 2026Q3 FY2026 report filed 5 Aug 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+351%10 yearsHigh $374.75Low $71.98
$0$100$200$300$400Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Cencora, Inc. reported revenue of $321.3 billion for fiscal year 2025 (the twelve months to 30 Sep 2025), up 9.3% from fiscal 2024. Net income was $1.55 billion and diluted earnings per share $7.96.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Jun 2026), revenue was $84.8 billion, up 5.1% from a year earlier.

Figures from Cencora, Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 5 Aug 2026.

Against Health Care

Growth
Top quarter
Revenue +11.1% a year over five years · 10th of 37
Profitability
Upper half
Return on invested capital 12.0%, five-year average · 16th of 38
Balance sheet
Lower half
Net debt 2.2× EBITDA · 20th of 38
Valuation
Below the median
P/E 26.0 · 14th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$321.3B+9.3%
Net income
$1.55B+3.0%
Diluted EPS
$7.96+5.7%
Gross margin
3.6%+0.2 pts
Free cash flow
$3.21B+7.0%
Net debt
$4.98B+99.8%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$100B$0$100B$200B$300B$400BRevenue, FY16: $146.85BNet income, FY16: $1.43BFY16Revenue, FY17: $153.14BNet income, FY17: $364.48MFY17Revenue, FY18: $167.94BNet income, FY18: $1.66BFY18Revenue, FY19: $179.59BNet income, FY19: $855.37MFY19Revenue, FY20: $189.89BNet income, FY20: −$3.41BFY20Revenue, FY21: $213.99BNet income, FY21: $1.54BFY21Revenue, FY22: $238.59BNet income, FY22: $1.7BFY22Revenue, FY23: $262.17BNet income, FY23: $1.75BFY23Revenue, FY24: $293.96BNet income, FY24: $1.51BFY24Revenue, FY25: $321.33BNet income, FY25: $1.55BFY25

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-5%-2.5%0%2.5%5%3.6%0.8%0.5%FY16FY19FY22FY25

Latest quarter · Q3 FY2026 to 30 Jun 2026, filed 5 Aug 2026 · Full results →

Revenue
$84.75B+5.1% on a year
Gross margin
4.3%+0.7 pts on a year
Operating income
$1.12B+29.1% on a year
Net income
$763.5M+11.1% on a year
Diluted EPS
$3.94+11.9% on a year
Free cash flow
$2.43B

Comparable companies All of Health Care →

Cencora, Inc. beside the other S&P 500 members in Health Care Distributors, then the largest in Health Care, by market value.

Cencora, Inc. and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
CencoraCOR$68.14B+2.8%−1.2%+5.1%0.8%26.0
McKesson CorporationMCK$127.9B+2.4%+31.2%+8.2%1.1%27.2
Cardinal HealthCAH$65.30B+1.1%+37.6%+10.0%0.7%35.9
Henry ScheinHSIC$9.29B+0.1%+18.4%+6.2%3.1%22.1
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Cencora, Inc. revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Cencora, Inc. revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
U.S. Healthcare Solutions$202.5B$212.1B+4.8%$229.3B+8.1%$259.6B+13.2%$285.0B+9.8%
International Healthcare Solutions$11.53B$26.49B+130%$25.65B−3.2%$26.74B+4.2%$28.33B+6.0%
Other——$7.36B$7.74B+5.1%$8.16B+5.4%
Total revenue$214.0B$238.6B$262.2B$294.0B$321.3B

Financial statements

Fiscal years, the latest ending 30 Sep 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Cencora, Inc. income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$146.8B$153.1B$167.9B$179.6B$189.9B$214.0B$238.6B$262.2B$294.0B$321.3B
Revenue growth+8.0%+4.3%+9.7%+6.9%+5.7%+12.7%+11.5%+9.9%+12.1%+9.3%
Gross profit$4.27B$4.55B$4.61B$5.14B$5.19B$6.94B$8.30B$8.96B$9.91B$11.48B
Operating income$1.53B$1.06B$1.44B$1.11B−$5.14B$2.35B$2.37B$2.34B$2.18B$2.63B
Net income$1.43B$364.5M$1.66B$855.4M−$3.41B$1.54B$1.70B$1.75B$1.51B$1.55B
Diluted EPS$6.32$1.64$7.53$4.04−$16.65$7.39$8.04$8.53$7.53$7.96
Gross margin2.9%3.0%2.7%2.9%2.7%3.2%3.5%3.4%3.4%3.6%
Operating margin1.0%0.7%0.9%0.6%−2.7%1.1%1.0%0.9%0.7%0.8%
Net margin1.0%0.2%1.0%0.5%−1.8%0.7%0.7%0.7%0.5%0.5%

Cash flow

Cencora, Inc. cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$3.18B$1.50B$1.41B$2.34B$2.21B$2.67B$2.70B$3.91B$3.48B$3.88B
Capital expenditure$464.6M$466.4M$336.4M$310.2M$369.7M$438.2M$496.3M$458.4M$487.2M$668.0M
Free cash flow$2.71B$1.04B$1.07B$2.03B$1.84B$2.23B$2.21B$3.45B$3.00B$3.21B

Balance sheet and shares

Cencora, Inc. balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$2.74B$2.44B$2.49B$3.37B$4.60B$2.55B$3.39B$2.59B$3.13B$4.36B
Total debt$4.19B$3.44B$4.17B$4.07B$4.50B$7.51B$6.73B$5.89B$5.62B$9.33B
Shareholders' equity$2.13B$2.06B$2.93B$2.88B−$1.02B$223.4M−$211.6M$522.0M$645.9M$1.51B
Diluted shares226M222M220M212M205M208M211M205M200M195M
Dividends per share$1.36$1.46$1.52$1.60$1.66$1.76$1.84$1.94$2.04$2.20

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Jun 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Cencora, Inc. quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$79.05B$81.49B$75.45B$80.66B$83.73B$85.93B$78.36B$84.75B
Revenue, year on year+14.7%+12.8%+10.3%+8.7%+5.9%+5.5%+3.8%+5.1%
Gross margin3.2%3.1%4.1%3.6%3.5%3.6%4.6%4.3%
Operating income$126.6M$706.3M$1.04B$867.7M$18.50M$760.4M$1.14B$1.12B
Net income$3.38M$488.6M$717.9M$687.4M−$339.7M$559.6M$1.64B$763.5M
Diluted EPS$0.02$2.50$3.68$3.52−$1.74$2.87$8.40$3.94
Free cash flow$818.1M−$2.82B$3.22B−$73.97M$2.88B−$2.42B$1.17B$2.43B

Operating KPIs

The operating figures Cencora, Inc. reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Cencora, Inc. operating KPIs
KPILatestPeriodChange on a yearRecent periods
Human Health revenue$74.3Bquarter to 30 Sep 2025up 5.7%
Alliance Healthcare revenue$6.6Bquarter to 30 Jun 2026up 6.0%
Animal Health revenue$1.5Bquarter to 30 Sep 2025up 5.6%
U.S. Healthcare Solutions revenue$74.9Bquarter to 30 Jun 2026up 4.9%
International Healthcare Solutions revenue$7.7Bquarter to 30 Jun 2026up 5.9%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Cencora, Inc.'s revenue in fiscal 2025?

$321.3 billion for fiscal year 2025 (the twelve months to 30 Sep 2025), as reported in its annual report.

What was Cencora, Inc.'s net income in fiscal 2025?

$1.55 billion for fiscal year 2025 (the twelve months to 30 Sep 2025).

What were Cencora, Inc.'s diluted earnings per share in fiscal 2025?

$7.96 for fiscal year 2025 (the twelve months to 30 Sep 2025).

What is Cencora, Inc.'s gross margin?

3.6% for fiscal year 2025 (the twelve months to 30 Sep 2025): gross profit divided by revenue.

What is Cencora, Inc.'s operating margin?

0.8% for fiscal year 2025 (the twelve months to 30 Sep 2025): operating income divided by revenue.

How much free cash flow did Cencora, Inc. generate in fiscal 2025?

$3.21 billion for fiscal year 2025 (the twelve months to 30 Sep 2025): operating cash flow less capital expenditure.

In the terminal

Twenty years of Cencora, Inc.'s figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans